During the past decade, Semmelweis University Heart Center conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 1 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Semmelweis University Heart Center" are "Acute Myocardial Infarction" (2 trials), "Cardiac Remodeling" (1 trials), "Heart Failure" (1 trials), "Pacing Therapy" (1 trials) and "Refractory Angina Pectoris" (1 trials). Many other conditions were trialed in "Semmelweis University Heart Center" in a lesser frequency.

Most popular intervention types in "Semmelweis University Heart Center" are "Device" (2 trials) and "Drug" (1 trials). Other intervention types were less common.

The name of intervention was led by "Dual Site Pacing" (1 trials), "MI size at 48-72 hours" (1 trials), "Nitric Oxide" (1 trials), "Single Site Pacing" (1 trials) and "device for Extracorporeal Shockwave Myocardial Revascularization (ESMR) therapy" (1 trials). Other intervention names were less common.

The vast majority of trials in "Semmelweis University Heart Center" are 3 trials for "All" genders.

Currently, there are NaN active trials in "Semmelweis University Heart Center". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Semmelweis University Heart Center, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Semmelweis University Heart Center, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".